The influence of reactive oxygen species on cell cycle progression in mammalian cells

Gene

Volumn 511, Issue 1, 2012, Pages 1-6

  Verbon, Eline Hendrike ^a   Post, Jan Andries ^a   Boonstra, Johannes ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cell cycle; Phosphorylation; ROS; Transactivation; Ubiquitination

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE PHOSPHATASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; HUMAN; MAMMAL CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; UBIQUITINATION;

ANIMALS; CDC25 PHOSPHATASES; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; CYCLIN-DEPENDENT KINASES; CYCLINS; HUMANS; MAMMALS; MODELS, BIOLOGICAL; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; UBIQUITINATION;

MAMMALIA;

EID: 84867659145     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.08.038     Document Type: Review

References (72)

1. Bedard K., Krause K. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 2007, 87:245-313.
2. Blanchetot C., Boonstra J. The ROS-NOX connection in cancer and angiogenesis. Crit. Rev. Eukaryot. Gene Expr. 2008, 18:35-45.
3. Boonstra J., Post J.A. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 2004, 337:1-13.
4. Boriello A., Cucciolla V., Oliva A., Zappia V., Ragione F.D. p27Kip1 metabolism, a fascinating labyrinth. Cell Cycle 2007, 6:1053-1061.
5. Boutros R., Dozier C., Ducommun B. The when and wheres of CDC25 phosphatases. Curr. Opin. Cell Biol. 2006, 18:185-191.
6. Brisson M., et al. Redox regulation of Cdc25B by cell-active quinolinediones. Mol. Pharmacol. 2005, 68:1810-1820.
7. Carcagno A.L., et al. E2F1-mediated upregulation of p19INK4d determines its periodic expression during cell cycle and regulates cellular proliferation. PLoS One 2011, 6. (e21938-e21938).
8. Carmi C., et al. Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides. J. Med. Chem. 2012, 55:2251-2264.
9. Cheng M., et al. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 1999, 18:1571-1583.
10. Chiarugi P., Buricchi F. Protein tyrosine phosphorylation and reversible oxidation: two cross-talking posttranslation modifications. Antioxid. Redox Signal. 2007, 9:1-24.
11. Deshpande S.S., Irani K. Oxidant signalling in carcinogenesis: a commentary. Human Exp. Toxicol. 2002, 21:63-64.
12. de Wit R., Capello A., Boonstra J., Verkleij A.J., Post J.A. Hydrogen peroxide inhibits epidermal growth factor receptor internalization in human fibroblasts. Free Radic. Biol. Med. 1999, 28:28-38.
13. Domingo-Sananes M.R., Kapuy O., Hunt Y., Novak B. Switches and latches: a biochemical tug-of-war between the kinases and phosphatases that control mitosis. Philos. Trans. R. Soc. B 2011, 366:3584-3594.
14. Donkó Á., Péterfi Z., Sum A., Leto T., Geiszt M. Dual oxidases. Philos. Trans. R. Soc. B Biol. Sci. 2005, 360:2301-2308.
15. Dröge W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82:47-95.
16. Fiaschi-Taesch N., Sicari B., Ubriani K., Cozar-Castellano I., Takane K.K., Stewart A.F. Mutant parathyroid hormone-related protein, devoid of the nuclear localization signal, markedly inhibits arterial smooth muscle cell cycle and neointima formation by coordinate up-regulation of p15Ink4b and p27kip1. Endocrinology 2009, 150:1429-1439.
17. Freinbichler W., et al. Highly reactive oxygen species: detection, formation and possible functions. Cell. Mol. Life Sci. 2011, 68:2067-2079.
18. Giacinti C., Giordano A. RB and cell cycle progression. Oncogene 2006, 25:5220-5227.
19. Gopinathan L., Ratnacaram C.K., Kaldis P. Established and novel Cdk/cyclin complexes regulating the cell cycle and development. Cell Cycle in Development 2011, 365-389. Springer Verlag Berlin Heidelberg. J.Z. Kubiak (Ed.).
20. Griendling K.K., Sorescu D., Lassègue B., Ushio-Fukai M. Modulation of protein kinase activit and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2175-2183.
21. Havens C.G., Ho A., Yoshioka N., Dowdy S.F. Regulation of late G1/S phase transition and APCCdh1 by reactive oxygen species. Mol. Cell. Biol. 2006, 26:4701-4711.
22. Hoffmann I., Clarke P.R., Marcote M.K., Karsenti E., Draetta G. Phosphorylation and activation of human Cdc25-C by cdc2-cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J. 1993, 12:53-63.
23. Hoffmann I., Draetta G., Karsenti E. Activation of the phosphatase activity of human Cdc25A by a CDK2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 1994, 13:4302-4310.
24. Huang S., Zhang A., Ding G., Chen R. Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation. Am. J. Physiol. Renal Physiol. 2009, 296:F1323-F1333.
25. Inoguchi T., et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. JASN 2003, 14:s227-s232.
26. Inoue S., et al. Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer. PLoS One 2012, 7:e31090.
27. Jiang F., Zhang Y., Dusting G.J. NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol. Rev. 2011, 63:218-242.
28. Karagoz I.D., et al. CDC 25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma. Tumour Biol. 2010, 31:597-604.
29. Katsuyama M., Matsuno K., Yabe-Nishimura C. Physiological roles of NOX/NADPH oxidase, the superoxide-generating enzyme. J. Clin. Biochem. Nutr. 2012, 50:9-22.
30. Klein J.D., Christopoulos A., Ahn S.M., Gooding W.E., Grandis J.R., Kim S. Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma. Head Neck 2012, 34:1269-1276.
31. Lambeth J.D. NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol. 2004, 4:181-189.
32. Lammer C., Wagerer S., Saffrich R., Mertens D., Ansorge W., Hoffmann I. The Cdc25B phosphatase is essential for the G2/M phase transition in human cells. J. Cell Sci. 1998, 111:2445-2453.
33. Lavecchia A., Di Giovanni C., Novellino E. Cdc25a and b dual-specificity phosphatases inhibitors: protential agents for cancer therapy. Curr. Med. Chem. 2009, 16:1831-1849.
34. Léon-Buitimea A., Rodríguez-Fragoso L., Lauer F.T., Bowles H., Thompson T.A., Burchiel S.W. Ethanol-induced oxidative stress is associated with EGF receptor phosphorylation in MCF-10A cells overexpressing CYP2E1. Toxicol. Lett. 2012, 209:161-165.
35. Li X., et al. Localization changes of endogenous hydrogen peroxide during cell division cycle of Xanthomonas. Mol. Cell. Biochem. 2007, 300:207-213.
36. Lu Z., Hunter T. Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1 and p57Kip2 CDK inhibitors. Cell Cycle 2010, 9:2342-2352.
37. Luanpitpong S., et al. Mitochondrial superoxide mediates doxorubicin-induced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitination. Biochem. Pharmacol. 2012, 15:1643-1654.
38. Mairet-Coello G., Tury A., Buskirk E., van Robinson K., Genestine M., DiCicco-Bloom E. p57KIP2 regulates radial glia and intermediate precursor cell cycle dynamics and lower layer neurogenesis in developing cerebral cortex. Development 2012, 139:475-487.
39. Martien S., Abbadie C. Acquisition of oxidative DNA damage during senescence: the first step toward carcinogenesis?. Ann. N. Y. Acad. Sci. 2007, 1119:51-63.
40. Mazak I., et al. Aldosterone potentiates angiontensin II-induced signaling in vascular smooth muscle cells. Circulation 2004, 109:2792-2800.
41. Molenaar J.J., et al. Copy number defects of G1-Cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes Chromosomes Cancer 2012, 51:10-19.
42. Naderi A., Liu J. Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer. Cancer Lett. 2010, 298:74-87.
43. Nicholson R.I., Gee J.M.W., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 2001, 37:9-15.
44. Obaya A.J., Sedivy J.M. Regulation of cyclin-Cdk activity in mammalian cells. Cell. Mol. Life Sci. 2002, 59:126-142.
45. Pan Y., et al. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4 and VEGFR2, displays potent antitumor activity both in vitro and in vivo. Mol. Cancer Ther. 2012, 11:952-962.
46. Papaiahgari S., Zhang Q., Kleeberger S.R., Cho H., Reddy S.P. Hyperoxia stimulates an Nrf2-ARE transcriptional response via ROS-EGFR-PI3K-Akt/ERK MAP kinase signaling in pulmonary epithelial cells. Antioxid. Redox Signal. 2006, 8:43-52.
47. Pelicano H., Carney D., Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat. 2004, 7:97-110.
48. Pereg Y., et al. Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A. Nat. Cell Biol. 2010, 12:400-406.
49. Qin Y., Pan X., Tang T., Zhou L., Gong X. Anti-proliferative effects of the novel squamosamide derivative (FLZ) on HepG2 human hepatoma cells by regulating the cell cycle-related proteins are associated with decreased Ca2+/ROS levels. Chem. Biol. Interact. 2011, 193:246-253.
50. Ralph S.J., Rodríquez-Enríquez S., Neuzil J., Saavedra E., Moreno-Sánchez R. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy. Mol. Aspects Med. 2010, 31:145-170.
51. Romeo Y., Zhang X., Roux P.P. Regulation and function of the RSK family of protein kinases. Biochem. J. 2012, 441:553-569.
52. Saab R., et al. p18Ink4cand p53 act as tumor suppressors in Cyclin D1-driven primitive neuroectodermal tumor. Cancer Res. 2009, 69:440-448.
53. Sakamoto K., Ohki K., Saito M., Nakahara T., Ishii K. Small molecule cyclin-dependent kinase inhibitors protect against neuronal cell death in the ischemic-reperfused rat retina. J. Ocul. Pharmacol. Ther. 2011, 27:419-425.
54. Santamaría D., et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007, 448:811-815.
55. Satyanarayana A., Kaldis P. Mammalian cell-cycle regulation: several CDKs, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009, 28:2925-2939.
56. Sortino M.A., et al. Novel neuronal targets for the acetylcholinesterase inhibitor donepezil. Neuropharmacology 2004, 47:1198-1204.
57. Starostina N.G., Kipreos E.T. Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors. Trends Cell Biol. 2011, 22:33-41.
58. Stöckl P., Hütter E., Zwerschke W., Jansen-Dürr P. Sustained inhibition of oxidative phosphorylation impairs cell proliferation and induces premature senescence in human fibroblasts. Exp. Gerontol. 2006, 41:674-682.
59. Suh Y., et al. Cell transformation by the superoxide generating oxidase Mox1. Nature 1999, 401:79-82.
60. Tagawa M., Kawamura L., Li Q., Tada Y., Hiroshima K., Shimada H. A possible anticancer agent, type III interferon, activates cell death pathways and produces antitumor effects. Clin. Dev. Immunol. 2011, (article ID 479013).
61. Taylor M.A., Lee Y.H., Schiemann W.P. Role of TGF-β and the tumor microenvironment during mammary tumorigenesis. Gene Expr. 2011, 15:117-132.
62. Turowski P., Franckhauser C., Morris M.C., Vaglio P., Fernandez A., Lamb N.J.C. Functional Cdc25C dual-specificity phosphatase is required for S-phase entry in human cells. Mol. Biol. Cell 2003, 14:2984-2998.
63. Vijayakumar S., et al. High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A. Cancer Cell 2011, 19:601-612.
64. Viry E., Anwar A., Kirsch G., Jacob C., Diederick M., Bagrel D. Antiproliferative effect of natural tetrasulfides in human breast cancer cells is mediated through the inhibition of the cell division cycle 25 phosphatases. Int. J. Oncol. 2011, 38:1103-1111.
65. Wind S., et al. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br. J. Pharmacol. 2010, 161:885-898.
66. Wu L., et al. Molecular cloning of the human CAK1 gene encoding a cyclin-dependent kinase-activating kinase. Oncogene 1994, 9:2089-2096.
67. Wu Y., et al. A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation. Cancer Prev. Res. 2010, 3:818-828.
68. Yamaura M., et al. NADPH oxidase 4 contributes to transformation phenotype of melanoma cells by regulating G2-M cell cycle progression. Cancer Res. 2009, 69:2647-2654.
69. Yarden Y. The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur. J. Cancer 2001, 37:S3-S8.
70. Yunbo L., Trush M.A. Dephenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. Biochem. Biophys. Res. Commun. 1998, 253:296-299.
71. Zhang Y., Zhao W., Zhang H.J., Domann F.E., Oberley L.W. Overexpression of copper zinc superoxide dismutase suppresses human glioma cell growth. Cancer Res. 2002, 62:1205-1212.
72. Zhou Y., et al. LGH00031, a novel ortho-quinonoid inhibitor of cell division cycle 25B, inhibits human cancer cells via ROS generation. Acta Pharmacol. Sin. 2009, 30:1359-1368.